Advertisement

Banner Fairtec GmbH Worldwide Event Solutions 600x60px
Document › Details

Orexo AB. (9/16/11). "Press Release: Orexo Strengthens Its Commercial Knowhow and Appoints Nikolaj Sørensen as Chief Commercial Officer". Uppsala.

Region Region Uppsala
  Country Sweden
Organisations Organisation Orexo AB (OMX Nordic List, Mid Cap: ORX)
  Group Orexo (Group)
  Organisation 2 Pfizer AB
Products Product pain drug
  Product 2 anti-inflammatory drug
Persons Person Sørensen, Nikolaj (Orexo 201110– CCO before Pfizer AB + Boston Consulting Group)
  Person 2 Lundström, Anders (Orexo 201102– CEO before Biogen Idec + AstraZeneca + Janssen-Cilag + BMS)
     


Orexo AB (STO: ORX) appoints Nikolaj Sørensen as Chief Commercial Officer effective October 1, 2011. Nikolaj has extensive experience of the pharmaceutical industry and will be responsible for Orexo's commercial operations as well as development of the company's commercial strategies. His international commercial experience is a key asset in Orexo's goal to develop, market and sell proprietary products. Nikolaj will be reporting to the CEO and will be part of the company's executive management team.

Nikolaj Sørensen has a Master of Science in Business and Economics and previously worked at Pfizer where he was i.a. Director and Brand Team Leader for Pfizer's leading pain treatment product in Europe and Canada. At Pfizer, Nikolaj also worked as Head of Business Development and Director of Strategic Planning, acted as Business Area Director for primary care products, and as Managing Director and Chairman of the board for Pfizer AB. In addition, Nikolaj has been a member of the Board of the Swedish Pharmaceutical Industry Association (LIF) for the past few years.

Prior to working at Pfizer, Nikolaj was a consultant at Boston Consulting Group (BCG), focusing on life science and among other he was the Project Leader for the merger of Pfizer and Pharmacia in the Nordic region.

"Orexo is an exciting company that I have followed for several years. The company has a very interesting product portfolio that provides a solid foundation for a commercial organization. I look forward to developing and executing Orexo's strategy for sales and marketing of the company's own products," said Nikolaj Sørensen.

"Orexo has had a strong focus on commercial development since 2010 and we are particularly pleased that we have succeeded in recruiting Nikolaj Sørensen to be in charge of commercial operations. He brings broad international commercial experience and his background suits the company's strategy to market and sell its own products," said Anders Lundström, President and CEO of Orexo AB. "I am very happy to welcome Nikolaj to Orexo's executive management team."

For further information, please contact:
Anders Lundström, President and CEO, Orexo AB
Tel: +46 706 67 22 66
E-mail: anders.lundstrom@orexo.com


About Orexo

Orexo is a pharmaceutical company focusing on developing treatments for pain and inflammation. The company has four commercialized products, several projects developed in partnership as well as three proprietary development programs. Orexo's registered products are Abstral® for the treatment of break through cancer pain, sold by Kyowa Hakko Kirin/ProStrakan Group plc. in Europe and in the USA, the sleeping pill Edluar™, sold by Meda in the USA, as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary Kibion. More information can be found at www.orexo.com.

Note

Orexo AB (publ) discloses the information provided in this press release pursuant to the Securities Markets Act. The information was provided for public release on September 16, 2011 at 10:30a.m. CET. This press release has been prepared in both Swedish and English. In the event of any discrepancy in the content of the two versions, the Swedish version shall take precedence.

   
Record changed: 2012-03-12

Advertisement

Banner EBD Group BIO Europe 2014 BEU Frankfurt November 600x60px

More documents for Orexo (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Banner Fairtec GmbH We Optimise the ROI of Your Event 600x60px




» top

Advertisements

Banner C5 Communications Life Sciences IP Summit 2014 Amsterdam 120x180px Banner EBD Group BIO Europe 2013 BEU Frankfurt November 120x180px The Events Group Pharm Connect Congress 2015 Budapest February 120x180px Highl Successful LC/MS Niche Player Is Looking for a Junior Partner 120x240px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Banner [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px